Faecalibacterium prausnitzii and human intestinal health.

By S. Miquel, Rebeca Martín, O. Rossi, L. Bermúdez-Humarán, J. Chatel, Harry Sokol, Muriel Thomas, M. Thomas, J. Wells, P. Langella. Current Opinion in Microbiology, 2013

1,110 citations recorded by the source corpus.

Subfields: Gastroenterology, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4a970842807b461708fdd658eb1a2cff4bccf79a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

S. Duncan

In Infectious Diseases

In Molecular Biology

Citations in the corpus

Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota (2023, background): “In the case of the Ruminococcaceae family, Faecalibacterium prausnitzii represents up to 5% of the fecal microbiota of healthy adults, being one of the most abundant butyrate-producing bacteria [102,103].”
Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria (2017, background): “It is thus interesting to mention that Faecalibacterium prausnitzii, the first anti-inflammatory commensal bacterium identified on the basis of human clinical data, is also one of the major butyrate-producer of the human intestinal microbiota [25, 26].”
Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease (2015, background): “prausnitzii exhibits anti-inflammatory effects both in vitro (cellular models) and in vivo (TNBS colitis model), associated with secreted metabolites that block NF-κB activation and IL-8 production by intestinal epithelial cells [14] [16] [17-18].”
Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics (2017, background): “prausnitzii depletion in adult CD (Martinez-Medina et al., 2006; Frank et al., 2007; Sokol et al., 2008b, 2009; Swidsinski et al., 2008; Willing et al., 2009; Fujimoto et al., 2013; Miquel et al., 2013), UC (Swidsinski et al.”
The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome (2020, background): “It should also be noted that Faecalibacterium prausnitzii is the first anti-inflammatory commensal bacterium identified on the basis of human clinical data and is also one of the major butyrate-producer of the human intestinal microbiome [20,21].”
Dysbiosis of the gut microbiota in disease (2015, background): “In CD, the predominant dysbiosis has been described to be associated with five bacterial species amongst which alterations in the abundance of Faecalibacterium prausnitzii is associated with the prolongation of disease remission (32, 33), with this bacterium having a therapeutic effect in experiment”
Human Intestinal Barrier Function in Health and Disease (2016, background): “of the phylum Firmicutes is a common signature of fecal microbiota of Crohn’s disease patients and in particular decreased abundance of Faecalibacterium prausnitzi.(49)”
Intestinal permeability – a new target for disease prevention and therapy (2014, background): “The microbiota is implicated in these physiological changes for example via reduced numbers of butyrate producers and butyrate production [62,63], thereby contributing to the pathophysiology of inflammatory diseases [64].”
Probiotics, gut microbiota, and their influence on host health and disease (2017, neutral): “prausnitzii, one of the “emerging probiotics” [102].”
Meta-analyses of human gut microbes associated with obesity and IBD (2014, background): “sible for causing inappropriate immune responses in the host [47–49], as well as opening up niches for occupation by invasive or pro-inflammatory species.”